Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buchanan, T. A.
Right arrow Articles by Azen, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buchanan, T. A.
Right arrow Articles by Azen, S. P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:2796-2803, 2002
© 2002 by the American Diabetes Association, Inc.

Preservation of Pancreatic ß-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women

Thomas A. Buchanan1,2,3, Anny H. Xiang3,4, Ruth K. Peters3,4, Siri L. Kjos2,3, Aura Marroquin1, Jose Goico1, Cesar Ochoa1, Sylvia Tan4, Kathleen Berkowitz2, Howard N. Hodis1,3,4, and Stanley P. Azen3,4

1 Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California
2 Department of Obstetrics and Gynecology, University of Southern California Keck School of Medicine, Los Angeles, California
3 Diabetes Research Center, University of Southern California Keck School of Medicine, Los Angeles, California
4 Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California

Type 2 diabetes frequently results from progressive failure of pancreatic ß-cell function in the presence of chronic insulin resistance. We tested whether chronic amelioration of insulin resistance would preserve pancreatic ß-cell function and delay or prevent the onset of type 2 diabetes in high-risk Hispanic women. Women with previous gestational diabetes were randomized to placebo (n = 133) or the insulin-sensitizing drug troglitazone (400 mg/day; n = 133) administered in double-blind fashion. Fasting plasma glucose was measured every 3 months, and oral glucose tolerance tests (OGTTs) were performed annually to detect diabetes. Intravenous glucose tolerance tests (IVGTTs) were performed at baseline and 3 months later to identify early metabolic changes associated with any protection from diabetes. Women who did not develop diabetes during the trial returned for OGTTs and IVGTTs 8 months after study medications were stopped. During a median follow-up of 30 months on blinded medication, average annual diabetes incidence rates in the 236 women who returned for at least one follow-up visit were 12.1 and 5.4% in women assigned to placebo and troglitazone, respectively (P < 0.01). Protection from diabetes in the troglitazone group 1) was closely related to the degree of reduction in endogenous insulin requirements 3 months after randomization, 2) persisted 8 months after study medications were stopped, and 3) was associated with preservation of ß-cell compensation for insulin resistance. Treatment with troglitazone delayed or prevented the onset of type 2 diabetes in high-risk Hispanic women. The protective effect was associated with the preservation of pancreatic ß-cell function and appeared to be mediated by a reduction in the secretory demands placed on ß-cells by chronic insulin resistance.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
M. H. Black, T. E. Fingerlin, H. Allayee, W. Zhang, A. H. Xiang, E. Trigo, J. Hartiala, A. B. Lehtinen, S. M. Haffner, R. N. Bergman, et al.
Evidence of Interaction Between PPARG2 and HNF4A Contributing to Variation in Insulin Sensitivity in Mexican Americans
Diabetes, April 1, 2008; 57(4): 1048 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
J. N Davis, K. E Alexander, E. E Ventura, L. A Kelly, C. J Lane, C. E Byrd-Williams, C. M Toledo-Corral, C. K Roberts, D. Spruijt-Metz, M. J Weigensberg, et al.
Associations of dietary sugar and glycemic index with adiposity and insulin dynamics in overweight Latino youth
Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1331 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
M. J. Franz
Themed Review: Lifestyle Interventions Across the Continuum of Type 2 Diabetes: Reducing the Risks of Diabetes
American Journal of Lifestyle Medicine, October 1, 2007; 1(5): 327 - 334.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
The Avandia Debate
Diabetes Care, September 1, 2007; 30(9): 2401 - 2408.
[Full Text] [PDF]

Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
C. W. Spellman
Insulin Therapy for Maximal Glycemic Control in Type 2 Diabetes Mellitus
J Am Osteopath Assoc, July 1, 2007; 107(7): 260 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
F. W.F. Hanna, J. R. Peters, J. Harlow, and P. W. Jones
Discrepancy Between Postnatal and Antenatal Management of Gestational Diabetes in the U.K.
Diabetes Care, July 1, 2007; 30(7): e64 - e64.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. L. Kitzmiller, L. Dang-Kilduff, and M. M. Taslimi
Gestational Diabetes After Delivery: Short-term management and long-term risks
Diabetes Care, July 1, 2007; 30(Supplement_2): S225 - S235.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
R. E. Ratner
Prevention of Type 2 Diabetes in Women With Previous Gestational Diabetes
Diabetes Care, July 1, 2007; 30(Supplement_2): S242 - S245.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
S. E. Kahn and B. Zinman
Point: Recent Long-Term Clinical Studies Support an Enhanced Role for Thiazolidinediones in the Management of Type 2 Diabetes
Diabetes Care, June 1, 2007; 30(6): 1672 - 1676.
[Full Text] [PDF]

Home page
 DiabetesHome page
T. A. Buchanan
(How) Can We Prevent Type 2 Diabetes?
Diabetes, June 1, 2007; 56(6): 1502 - 1507.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
F. Chang, L. A Jaber, H. D Berlie, and M. B. O'Connell
Evolution of Peroxisome Proliferator-Activated Receptor Agonists
Ann. Pharmacother., June 1, 2007; 41(6): 973 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. P. Kim, M. Ellmerer, E. L. Kirkman, and R. N. Bergman
beta-Cell "rest" accompanies reduced first-pass hepatic insulin extraction in the insulin-resistant, fat-fed canine model
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1581 - E1589.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
M. D Oldfield, P. Donley, L. Walwyn, I. Scudamore, and R. Gregory
Long term prognosis of women with gestational diabetes in a multiethnic population
Postgrad. Med. J., June 1, 2007; 83(980): 426 - 430.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. B. Davidson
Clinical Implications of the DREAM Study: Response to Kanat
Diabetes Care, May 1, 2007; 30(5): e45 - e45.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Kim, D. K. Berger, and S. Chamany
Recurrence of Gestational Diabetes Mellitus: A systematic review
Diabetes Care, May 1, 2007; 30(5): 1314 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Kim, W. H. Herman, and S. Vijan
Efficacy and Cost of Postpartum Screening Strategies for Diabetes Among Women With Histories of Gestational Diabetes Mellitus
Diabetes Care, May 1, 2007; 30(5): 1102 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. Menzaghi, V. Trischitta, and A. Doria
Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease
Diabetes, May 1, 2007; 56(5): 1198 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
V. M Montori, W. L Isley, and G. H Guyatt
Waking up from the DREAM of preventing diabetes with drugs
BMJ, April 28, 2007; 334(7599): 882 - 884.
[Full Text] [PDF]

Home page
 Physiol. Rev.Home page
D. B. Savage, K. F. Petersen, and G. I. Shulman
Disordered Lipid Metabolism and the Pathogenesis of Insulin Resistance
Physiol Rev, April 1, 2007; 87(2): 507 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. L. Wajchenberg
{beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment
Endocr. Rev., April 1, 2007; 28(2): 187 - 218.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Tozzo, R. Ponticiello, J. Swartz, D. Farrelly, R. Zebo, G. Welzel, D. Egan, L. Kunselman, A. Peters, L. Gu, et al.
The Dual Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Activator Muraglitazar Prevents the Natural Progression of Diabetes in db/db Mice
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 107 - 115.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. Grant, A. S. Adams, C. M. Trinacty, F. Zhang, K. Kleinman, S. B. Soumerai, J. B. Meigs, and D. Ross-Degnan
Relationship Between Patient Medication Adherence and Subsequent Clinical Inertia in Type 2 Diabetes Glycemic Management
Diabetes Care, April 1, 2007; 30(4): 807 - 812.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. M. Nathan and M. Berkwits
Trials That Matter: Rosiglitazone, Ramipril, and the Prevention of Type 2 Diabetes
Ann Intern Med, March 20, 2007; 146(6): 461 - 463.
[Full Text] [PDF]

Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
M. J. Franz
The Evidence Is In: Lifestyle Interventions Can Prevent Diabetes
American Journal of Lifestyle Medicine, March 1, 2007; 1(2): 113 - 121.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
M. Cnop, J. Vidal, R. L. Hull, K. M. Utzschneider, D. B. Carr, T. Schraw, P. E. Scherer, E. J. Boyko, W. Y. Fujimoto, and S. E. Kahn
Progressive Loss of {beta}-Cell Function Leads to Worsening Glucose Tolerance in First-Degree Relatives of Subjects With Type 2 Diabetes
Diabetes Care, March 1, 2007; 30(3): 677 - 682.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. M. Nathan, M. B. Davidson, R. A. DeFronzo, R. J. Heine, R. R. Henry, R. Pratley, and B. Zinman
Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care
Diabetes Care, March 1, 2007; 30(3): 753 - 759.
[Full Text] [PDF]

Home page
 CJASNHome page
M. F. Crutchlow and R. D. Bloom
Transplant-Associated Hyperglycemia: A New Look at an Old Problem
Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 343 - 355.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo
Thiazolidinediones improve beta-cell function in type 2 diabetic patients
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. C. Gerstein
Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach
Diabetes Care, February 1, 2007; 30(2): 432 - 434.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Tuomilehto
Counterpoint: Evidence-Based Prevention of Type 2 Diabetes: The Power of Lifestyle Management
Diabetes Care, February 1, 2007; 30(2): 435 - 438.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. A. Abdul-Ghani, M. Matsuda, B. Balas, and R. A. DeFronzo
Muscle and Liver Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test
Diabetes Care, January 1, 2007; 30(1): 89 - 94.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. A. Moibi, D. Gupta, T. L. Jetton, M. Peshavaria, R. Desai, and J. L. Leahy
Peroxisome Proliferator-Activated Receptor-{gamma} Regulates Expression of PDX-1 and NKX6.1 in INS-1 Cells
Diabetes, January 1, 2007; 56(1): 88 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
L. E. John, M. P. Kane, R. S. Busch, and R. A. Hamilton
Expanded Use of Exenatide in the Management of Type 2 Diabetes
Diabetes Spectr, January 1, 2007; 20(1): 59 - 63.
[Full Text] [PDF]

Home page
 Am. J. Public HealthHome page
M. Tanaka, G. Jaamaa, M. Kaiser, E. Hills, A. Soim, M. Zhu, I. Y. Shcherbatykh, R. Samelson, E. Bell, M. Zdeb, et al.
Racial Disparity in Hypertensive Disorders of Pregnancy in New York State: A 10-Year Longitudinal Population-Based Study
Am J Public Health, January 1, 2007; 97(1): 163 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
American Diabetes Association
Standards of Medical Care in Diabetes--2007
Diabetes Care, January 1, 2007; 30(suppl_1): S4 - S41.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Rasouli, P. A Kern, E. A. Reece, and S. C. Elbein
Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes
Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E359 - E365.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. E. Kahn, S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. O'Neill, B. Zinman, et al.
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
N. Engl. J. Med., December 7, 2006; 355(23): 2427 - 2443.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. A. Fonseca and S. E. Kahn
Of Hopes and DREAMS: The Quest to Prevent Type 2 Diabetes
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4762 - 4763.
[Full Text] [PDF]

Home page
 DOC NewsHome page
S. E. Inzucchi
Diabetes Prevention
DOC News, November 1, 2006; 3(11): 3 - 19.
[Full Text]

Home page
 NEJMHome page
J. R. Ingelfinger and C. G. Solomon
Angiotensin-Converting-Enzyme Inhibitors for Impaired Glucose Tolerance -- Is There Still Hope?
N. Engl. J. Med., October 12, 2006; 355(15): 1608 - 1610.
[Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
The Diabetes Prevention Program Research Group [Pr
The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.
J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2006; 61(10): 1075 - 1081.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. B. Carr, K. M. Utzschneider, R. L. Hull, J. Tong, T. M. Wallace, K. Kodama, J. B. Shofer, S. R. Heckbert, E. J. Boyko, W. Y. Fujimoto, et al.
Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes.
Diabetes Care, September 1, 2006; 29(9): 2078 - 2083.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. T. Ackermann, T. J. Thompson, J. V. Selby, M. M. Safford, M. Stevens, A. F. Brown, and K.M. V. Narayan
Is the Number of Documented Diabetes Process-of-Care Indicators Associated With Cardiometabolic Risk Factor Levels, Patient Satisfaction, or Self-Rated Quality of Diabetes Care?: The Translating Research into Action for Diabetes (TRIAD) study.
Diabetes Care, September 1, 2006; 29(9): 2108 - 2113.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Droumaguet, B. Balkau, D. Simon, E. Caces, J. Tichet, M. A. Charles, E. Eschwege, and the DESIR Study Group
Use of HbA1c in Predicting Progression to Diabetes in French Men and Women: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR)
Diabetes Care, July 1, 2006; 29(7): 1619 - 1625.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
L. S. Phillips, W. S. Weintraub, D. C. Ziemer, P. Kolm, J. K. Foster, V. Vaccarino, M. K. Rhee, R. K. Budhwani, and J. M. Caudle
All Pre-Diabetes Is Not the Same: Metabolic and Vascular Risks of Impaired Fasting Glucose at 100 Versus 110 mg/dl: The Screening for Impaired Glucose Tolerance Study 1 (SIGT 1).
Diabetes Care, June 1, 2006; 29(6): 1405 - 1407.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. N. Leroyer, J. Tordjman, G. Chauvet, J. Quette, C. Chapron, C. Forest, and B. Antoine
Rosiglitazone Controls Fatty Acid Cycling in Human Adipose Tissue by Means of Glyceroneogenesis and Glycerol Phosphorylation
J. Biol. Chem., May 12, 2006; 281(19): 13141 - 13149.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. A. Abdul-Ghani, D. Tripathy, and R. A. DeFronzo
Contributions of {beta}-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose
Diabetes Care, May 1, 2006; 29(5): 1130 - 1139.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. I. Parvanova, R. Trevisan, I. P. Iliev, B. D. Dimitrov, M. Vedovato, A. Tiengo, G. Remuzzi, and P. Ruggenenti
Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion.
Diabetes, May 1, 2006; 55(5): 1456 - 1462.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Festa, K. Williams, R. P. Tracy, L. E. Wagenknecht, and S. M. Haffner
Progression of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in Relation to Incident Type 2 Diabetes
Circulation, April 11, 2006; 113(14): 1753 - 1759.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. A. Ritzel, A. E. Butler, R. A. Rizza, J. D. Veldhuis, and P. C. Butler
Relationship Between {beta}-Cell Mass and Fasting Blood Glucose Concentration in Humans.
Diabetes Care, March 1, 2006; 29(3): 717 - 718.
[Full Text] [PDF]

Home page
 DiabetesHome page
K. Lobner, A. Knopff, A. Baumgarten, U. Mollenhauer, S. Marienfeld, M. Garrido-Franco, E. Bonifacio, and A.-G. Ziegler
Predictors of Postpartum Diabetes in Women With Gestational Diabetes Mellitus
Diabetes, March 1, 2006; 55(3): 792 - 797.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. M. Kanaya, C. Wassel Fyr, E. Vittinghoff, T. B. Harris, S. W. Park, B. H. Goodpaster, F. Tylavsky, and S. R. Cummings
Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.
Arch Intern Med, February 13, 2006; 166(3): 350 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. M. Utzschneider, R. L. Prigeon, D. B. Carr, R. L. Hull, J. Tong, J. B. Shofer, B. M. Retzlaff, R. H. Knopp, and S. E. Kahn
Impact of Differences in Fasting Glucose and Glucose Tolerance on the Hyperbolic Relationship Between Insulin Sensitivity and Insulin Responses
Diabetes Care, February 1, 2006; 29(2): 356 - 362.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. H. Xiang, R. K. Peters, S. L. Kjos, A. Marroquin, J. Goico, C. Ochoa, M. Kawakubo, and T. A. Buchanan
Effect of Pioglitazone on Pancreatic {beta}-Cell Function and Diabetes Risk in Hispanic Women With Prior Gestational Diabetes
Diabetes, February 1, 2006; 55(2): 517 - 522.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. M. Kendall
Thiazolidinediones: The case for early use
Diabetes Care, January 1, 2006; 29(1): 154 - 157.
[Full Text] [PDF]

Home page
 DiabetesHome page
T. Harrity, D. Farrelly, A. Tieman, C. Chu, L. Kunselman, L. Gu, R. Ponticiello, M. Cap, F. Qu, C. Shao, et al.
Muraglitazar, a Novel Dual ({alpha}/{gamma}) Peroxisome Proliferator-Activated Receptor Activator, Improves Diab